Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2025 07:02 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing...
December 17, 2025 09:00 ET | Source: Incyclix Bio

Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell

RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
December 11, 2025 11:05 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting killing of HER2+ breast cancer cells in combination with HER2-targeted chimeric antigen receptor modified T-cells (CAR-T).

Io Therapeutics announced today data demonstrating effectiveness of its RXR agonist IRX4204 for synergistic killing of HER2+ breast cancer with CAR-T cells
December 11, 2025 08:08 ET | Source: Biomerica, Inc.

Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio

Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and...
December 10, 2025 15:39 ET | Source: Alameda Health System

Alameda Health System wins equity award for breast cancer screening campaign

OAKLAND, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Alameda Health System (AHS) has been honored with the 2025 Quality Leaders Award (QLA) by the California Association of Public Hospitals and...
December 09, 2025 09:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium

Myriad Genetics will present new data in eight abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS).
December 08, 2025 08:30 ET | Source: Stemline Therapeutics, Inc.

Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium

In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as well as in both metastatic and early...
December 08, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

STAFFORD, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
December 03, 2025 10:00 ET | Source: 4D Path

4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial

Trial analysis published in JNCI predicts residual cancer burden from baseline H&E slides using 4D Path's fully automated, treatment predictive platform
November 27, 2025 08:47 ET | Source: Research and Markets

CD73 Inhibitors Pipeline Report 2025: an Up-to-date Competitor Evaluation in the Field of Antibodies, RNA and Small Molecules in Research and Development Inhibiting CD73

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD73 Inhibitors" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about CD73 Inhibitors...